Biblio
Found 32 results
Filters: Keyword is Alzheimer Disease [Clear All Filters]
.
2023.
.
2022. .
2022.
Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.. JAMA Neurol. 74(2):225-232.
.
2017. Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease.. Sci Rep. 6:18725.
.
2016. Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.. Neurobiol Aging. 40:155-63.
.
2016. Sex differences in metabolic aging of the brain: insights into female susceptibility to Alzheimer's disease.. Neurobiol Aging. 42:69-79.
.
2016. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity.. Neurobiol Aging. 36(7):2282-2295.
.
2015. Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.. Neurotherapeutics. 12(1):66-80.
.
2015. White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.. EBioMedicine. 2(12):1888-904.
.
2015. Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C-NMR study.. J Cereb Blood Flow Metab. 34(11):1749-60.
.
2014. Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study.. J Cereb Blood Flow Metab. 34(2):288-96.
.
2014. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention.. PLoS One. 8(11):e79977.
.
2013. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease.. J Alzheimers Dis. 37(2):403-19.
.
2013. Neurosteroids as regenerative agents in the brain: therapeutic implications.. Nat Rev Endocrinol. 9(4):241-50.
.
2013. .
2013. .
2013. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.. Adv Pharmacol. 64:327-71.
.
2012. Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid.. Neurobiol Aging. 33(8):1507-21.
.
2012. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.. Neurobiol Aging. 32(11):1949-63.
.
2011. 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease.. PLoS One. 6(7):e21788.
.
2011. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.
.
2011. Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.
.
2011. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.. Biochim Biophys Acta. 1800(10):1121-6.
.
2010. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.. Prog Brain Res. 182:77-96.
.
2010.